Pricing Strategies; Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Double-digit rises and falls in the average prices of recently-launched generics recorded by market researcher WaveData demonstrated the volatile pricing dynamics of the UK market in December.
A host of leading generics firms have been denied a requested order to prevent leaks and potentially harmful public allegations as part of multi-district litigation over generics pricing in the US.
The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.
A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.
As several generic presentations see treble-digit average price rises in the UK, the country’s health department has reacted with a raft of price concessions. However, these have not always matched the prices recorded by market researcher WaveData.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.